TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
Study: NCT00079911
Drug: valacyclovir hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valacyclovir hydrochloride
Study: NCT02986607
Drug: parathyroid hormon 1-84
Normalized name: Parathyroid hormone (1-84) human recombinant
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
Study: NCT02209012
Drug: Topical Solution Vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle PDT given in CP0108
Study: NCT00900757
Drug: Palonosetron (PALO)
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
Study: NCT03837964
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01846221
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
Study: NCT01609166
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 3% cream application in one side of the body, twice a day for 6 months
Study: NCT01668966
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
Study: NCT00861874
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 IV, Days 1-5
Study: NCT00861874
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
Study: NCT01947491
Drug: Vehicle Lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01947491
Drug: Vehicle Spray
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03320850
Drug: OnabotulinumtoxinA and Hydrogel admixture
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
Study: NCT00327743
Drug: larotaxel
Normalized name: Larotaxel
DrugBank: Larotaxel (DB12984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion on Day 1 of a 21-day cycle
Study: NCT02768441
Drug: Dexamphetamine
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
Study: NCT00724009
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
Study: NCT03091881
Drug: Granisetron 0.1 MG/ML
Normalized name: granisetron 0.1 MG/ML
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 0.1 MG/ML Will be given 10 min before spinal block
Study: NCT01670734
Drug: alirocumab SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous
Study: NCT04178642
Drug: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
Study: NCT02031640
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02031640
Drug: Albuterol/salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Study: NCT02205008
Drug: Early postoperative intraperitoneal chemothgerapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq
Study: NCT03184584
Drug: PBI-4050
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 200 mg capsules (800 mg total) administered orally, once daily
Study: NCT00571701
Drug: celebrex (celecoxib)
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
Study: NCT05158426
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
Study: NCT00446576
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02067663
Drug: Mirena
Normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The IUD will be placed as part of standard clinical care.
Study: NCT03086226
Drug: Fosravuconazole
Normalized name: Fosravuconazole
DrugBank: Fosravuconazole (DB15204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
Study: NCT03086226
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be the active comparator
Study: NCT01747538
Drug: Dose 1 gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT01747538
Drug: Dose 2 gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00704444
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe, 10-mg tablets
Study: NCT00704444
Drug: Ezetimibe + other lipid-lowering medication(s)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
Study: NCT00525616
Drug: Mabthera
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two IV perfusions of 1000mg at 15 days intervals
Study: NCT03960866
Drug: Phentolamine Mesylate Ophthalmic Solution 1%
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Sterile Ophthalmic Solution
Study: NCT02634788
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine sublingual spray delivered via single 100 μL spray
Study: NCT00691132
Drug: phenethyl isothiocyanate
Normalized name: Phenethyl Isothiocyanate
DrugBank: Phenethyl Isothiocyanate (DB12695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00487240
Drug: Insulin Lispro Protamine Suspension
Normalized name: Insulin Lispro Protamine Suspension and Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
Study: NCT00487240
Drug: Insulin Levemir
Normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
Study: NCT02892422
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study
Study: NCT02544425
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
Study: NCT02544425
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
Study: NCT02544425
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It will be administered 40mg/day PO or IV D1-3
Study: NCT02544425
Drug: L-asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
Study: NCT02544425
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6
Study: NCT02544425
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2
Study: NCT03540875
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT01221402
Drug: extended-release niacin (Niaspan)
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
Study: NCT00240994
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
Study: NCT00240994
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
Study: NCT00240994
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per recommendation
Study: NCT00240994
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
Study: NCT00746824
Drug: TM30339 and/or placebo
DrugBank: TM30339 (DB05085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
Study: NCT02095145
Drug: Pomegranate-Extract Pill
Normalized name: pomegranate extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03676296
Drug: Puerarin
Normalized name: PUERARIN
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
Study: NCT03155178
Drug: ChloraPrep
Normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
Study: NCT00032188
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00937040
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
Study: NCT00937040
Drug: OROS MPH Tablets
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
Study: NCT03572530
Drug: 5-Azacytidine (5-AZA) group 1
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks.
Study: NCT03572530
Drug: 5-Azacytidine (5-AZA) group 2
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks.
Study: NCT03572530
Drug: 5-Azacytidine (5-AZA) group 3
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks.
Study: NCT03596281
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg Q3W IV
Study: NCT03596281
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 or 300 mg Q3W IV
Study: NCT00000238
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no